The immunoglobulin market size in Europe is expected to grow at a CAGR of 8.28% from 2023 to 2028 and be worth USD 8.13 billion by 2028 from USD 5.46 billion in 2023.
The growing aging population and rising prevalence of immunodeficiency diseases majorly drive the growth of the Europe immunoglobulin market. Immunoglobulin blood tests play a crucial role in detecting and measuring the levels of immunoglobulin in the body, which are essential antibodies responsible for fighting off infections and diseases. Imbalances in immunoglobulin levels can lead to chronic conditions such as autoimmune disorders and genetic diseases. Autoimmune disorders, in particular, have become a significant concern in Europe, affecting approximately 10% of the population. Lifestyle factors such as changes in habits, exposure to toxins, medication, smoking, and obesity contribute to the development of autoimmune diseases. With over 80 different illnesses falling under the umbrella of autoimmune disorders, these conditions can result in organ dysfunction and adversely impact patients' quality of life. Considering these factors, the Europe immunoglobulin market holds a substantial share in the region. The market's growth is driven by the increasing demand for immunoglobulin therapies to address immunodeficiency diseases, autoimmune disorders, and other related conditions. This presents opportunities for healthcare providers, pharmaceutical companies, and other stakeholders to meet the growing need for immunoglobulin products and services in the region.
The growing awareness of immunoglobulin therapies among the European population further fuels the growth rate of the Europe immunoglobulin market. The rising prevalence of children's healthcare issues related to excessive immunoglobulin levels drives the European market growth. The growing healthcare expenditure dedicated to immunoglobulin treatments contributes to the growth of the European immunoglobulin market. Researchers and healthcare providers are focusing on advancing immunoglobulin therapies to address various chronic conditions affecting the population. Manufacturers play a crucial role in developing medical devices and equipment that facilitate the administration of immunoglobulin therapies. Moreover, factors such as ongoing research and development, government support, approvals of advanced therapies, and pharmaceutical industry contributions contribute to the regional market growth.
The high cost of therapies and testing devices is one of the major factors hampering the growth of the European immunoglobulin market. Limitations in infrastructure facilities in research laboratories, a shortage of skilled professionals and lengthy development timelines further hinder the European market growth. Furthermore, the presence of side effects such as headache, fever, rashes, and vomiting negatively impacts the market expansion in the European region.
This research report on the Europe immunoglobulin market has been segmented and sub-segmented into the following categories.
By Route of Administration:
By Indication:
By Form:
By End-user:
By Country:
Europe accounted for a prominent share of the global market in 2022 and is anticipated to grow at a healthy CAGR during the forecast period owing to the presence of these therapies in numerous hospitals and the increasing healthcare expenditure. The rapid adoption of immunoglobulin treatment for COVID-19 cases with governments implementing measures to facilitate its usage propel the European market growth. Germany led the market in Europe in 2022 and is expected to grow at a healthy CAGR during the forecast period owing to the establishment of clinical trials and research centers. The UK market is predicted to witness a notable share of the European market during the forecast period owing to the growing number of manufacturing facilities and emerging companies, supported by government approvals for immunoglobulin therapies targeting cancer and other chronic diseases. The availability of affordable treatment options and favorable reimbursement policies have bolstered the UK market growth.
KEY MARKET PLAYERS:
Grifols, CSL Behring, Takeda Pharmaceutical Company Limited, Octapharma and Kedrion are some of the major companies in the Europe immunoglobulin market.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 1400
Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM
Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: [email protected]
Reports By Region